SL 801

Drug Profile

SL 801

Alternative Names: CBS 9106; SL-801

Latest Information Update: 07 Dec 2016

Price : $50

At a glance

  • Originator CanBas
  • Developer Stemline Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Apoptosis stimulants; Cell cycle modulators; Exportin-1 protein inhibitors; Tumour suppressor protein p53 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer
  • Preclinical Haematological malignancies; Multiple myeloma

Most Recent Events

  • 02 Dec 2016 Preclinical trials in Haematological malignancies (Combination therapy) in USA
  • 02 Dec 2016 Preclinical trials in Multiple myeloma (Combination therapy) in USA
  • 03 Nov 2016 Stemline Therapeutics plans a phase I trial for Haematological malignancies in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top